Shanghai Fosun Pharmaceutical : ANNOUNCEMENT REGARDING THE PROGRESS UPDATE ON THE PARTICIPATION INTO THE SUBSTANTIAL ASSET RESTRUCTURING OF CHONGQING JIAN FENG CHEMICAL CO., LTD.(H SHARES)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT REGARDING THE PROGRESS UPDATE ON THE

PARTICIPATION INTO THE SUBSTANTIAL ASSET RESTRUCTURING OF CHONGQING JIAN FENG CHEMICAL CO., LTD.

Reference is made to the announcements of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') dated 11 September 2016 and 24 November 2016 (the ''Announcements'')in relation to the participation in the substantial asset restructuring of Chongqing Jian Feng Chemical Co., Ltd.* (''Jian Feng Chemical'') by the Company and its subsidiary Guilin Pharmaceutical Co., Ltd.* (''Guilin Pharmaceutical'') and the entering into of the Agreement on Asset Acquisition by Share Issuance (the ''Agreement on Asset Acquisition by Share Issuance'') and the Supplemental Agreement to the Agreement on Asset Acquisition by Share Issuance (the ''Supplemental Agreement'') with, among others, Jian Feng Chemical in relation to the related matters. Unless otherwise specified, capitalised terms used herein shall have the same meaning as defined in the Announcements.

PROGRESS ON TRANSACTION

On 24 July 2017, Jian Feng Chemical received the ''Approval on the Acquisition of Assets by Issue of Shares to Chongqing Chemical & Pharmaceutical Holdings (Group) Company Limited and others by Chongqing Jian Feng Chemical Co., Ltd.'' (Zheng Jian Xu Ke [2017] No. 1174) issued by China Securities Regulatory Commission (the ''Approval''), which approved the transactions contemplated under the Agreement on Asset Acquisition by Share Issuance and the Supplemental Agreement. The Approval shall be valid for 12 months commencing from the date of issue.

Shareholders and potential investors of the Company should note that the transactions under the Agreement and the Supplemental Agreement are still subject to completion. Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Chen Qiyu

Chairman

Shanghai, the PRC 24 July 2017

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive directors of the Company are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

* for identification purposes only